Interventional cardiology

JenaValve Appoints Duane Pinto, MD, MPH, as Chief Medical Officer

Retrieved on: 
Monday, October 24, 2022
Georgetown University, PMA, CE marking, Cardiovascular disease, SSAS, AHA, Federal, Beth Israel Deaconess Medical Center, JACC, Aortic stenosis, Dartmouth College, Technology, AR, MPH, Biostatistics, Qatar Investment Authority, GLOBE, Manuscript, FDA, TAVR, Report, Adrenal insufficiency, Leadership, Review, QIA, Research, Harvard T.H. Chan School of Public Health, Trial of the century, Harvard University, NEJM, CCI, Herpetology, Physician, Public health, Trilogy Systems, RMM, Patient, Harvard Medical School, Interventional cardiology, Aortic valve, Medical imaging, Medical device, Medicine, MD

IRVINE, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that Duane Pinto, MD, MPH, has been appointed as Chief Medical Officer.

Key Points: 
  • IRVINE, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that Duane Pinto, MD, MPH, has been appointed as Chief Medical Officer.
  • Before joining JenaValve, Dr. Pinto was an associate professor of Medicine at Harvard Medical School and served as the Chief of the Interventional Cardiology section at Beth Israel Deaconess Medical Center.
  • He is also a trained proctor for the newest transcatheter valves and invited around the world to advise and perform interventional cardiology procedures.
  • We are incredibly pleased to welcome Dr. Pinto to the JenaValve team, said John Kilcoyne, Chief Executive Officer.

NeoChord Announces Positive 1-year Follow-Up Data with Transcatheter NeXuS System for Mitral Chordal Repair Using Multiple Chords to a Single Anchor

Retrieved on: 
Wednesday, October 19, 2022
Montefiore Medical Center, MR, Adrenal insufficiency, Hospital, Disease, LVEF, Heart, Transcatheter arterial chemoembolization, Patient, Cardiovascular disease, Interventional cardiology, EFS, Safety, GLOBE, Mitral valve, Solution, Pharmaceutical industry, Medical device, Medical imaging

Based on this clinical expertise, the Transcatheter NeXuS system has been developed to broaden patient access with a catheter-based approach.

Key Points: 
  • Based on this clinical expertise, the Transcatheter NeXuS system has been developed to broaden patient access with a catheter-based approach.
  • NeoChord announced today positive results on the first, 1-year follow up patient in the Companys Global Early Feasibility Study (EFS) treated with the novel Transcatheter NeXuS system.
  • The NeoChord NeXuS Transcatheter Mitral Chordal Repair device is unique from other mitral valve repair technologies in maintaining a natural physiologic functionality of the mitral valve.
  • NeoChord is now adding the minimally invasive transcatheter chordal repair system NeoChord NeXuS to its portfolio and is underlining the leading position in degenerative mitral valve chordal treatment.

Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

Retrieved on: 
Thursday, October 20, 2022
FDA, Medical Devices, Health, Clinical Trials, Cardiology, Quality of life, Myocarditis, Decompensation, Cardiomyopathy, U.S. Securities and Exchange Commission, ECMO, Heart, PMA, TCT, PROTECT, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. FDA, Patient, IV, Security (finance), Nasdaq, History, NCSI, Conversation, Cardiogenic shock, Food, Interventional cardiology, Trial of the century, SCAI, MD, AMI, Pappalardo, Heart failure, Medicines and Healthcare products Regulatory Agency, Safety, Milliman, Coronary artery disease, Survival, PCI, Maini, FDA, Sea Around Us (organization), ABMD, Myocardial infarction, Pharmaceutical industry, Medical device, Birth control, Hospital, Silviculture, Impella

The FDAs action is another affirmation that Impella heart pumps are safe and effective for cardiogenic shock, high-risk PCI, post-cardiotomy cardiogenic shock, cardiogenic shock in the setting of myocarditis or cardiomyopathy, and right heart failure.

Key Points: 
  • The FDAs action is another affirmation that Impella heart pumps are safe and effective for cardiogenic shock, high-risk PCI, post-cardiotomy cardiogenic shock, cardiogenic shock in the setting of myocarditis or cardiomyopathy, and right heart failure.
  • In total, Abiomed completed five post-approval studies for Impella over the seven years since its initial PMA was received.
  • The totality of Impella data collected in the U.S., Europe and Japan demonstrates Impella improves outcomes and lowers costs.
  • Impella is the most studied heart pump in the history of the FDA, with studies being conducted from 2006 to the present.

Sheridan N. Meyers, MD, FACC, is being recognized by Continental Who's Who as a Top Pinnacle Achiever for his exemplary career in the Medical field and in acknowledgment of his work in Academia

Retrieved on: 
Monday, September 26, 2022
Lyceum-Northwestern University, American Board of Internal Medicine, United States Department of Veterans Affairs, American College, American Board of Commissioners for Foreign Missions, Feinberg School of Medicine, MD, Angioplasty, Hospital, Medical degree, Catheter, Echocardiography, Army of the United States, McGaw Medical Center, Internal medicine, Interventional cardiology, Order of United Commercial Travelers of America, ABIM, Commercial, Cardiovascular disease, Birth, Heart, Medicine, Multimedia, MASH, American College of Cardiology, Education, Emeritus, Mentorship, View, John H. Stroger Jr. Hospital of Cook County, Science, Cardiology, Northwestern Memorial Hospital, Chemistry, Biology

During his practice, Dr. Meyers worked primarily in the cardiac catheterization lab, specializing in angioplasty and echocardiography to determine the appropriate diagnoses of various heart disorders.

Key Points: 
  • During his practice, Dr. Meyers worked primarily in the cardiac catheterization lab, specializing in angioplasty and echocardiography to determine the appropriate diagnoses of various heart disorders.
  • Cardiology is a branch of medicine that deals with the diseases of the heart and some parts of the circulatory system.
  • In pursuit of his medical career, Dr. Meyer obtained a Bachelor of Science in Biology and Chemistry from Northwestern University.
  • He earned his Medical Degree from Northwestern Medical School in 1961.

Dr. Lawrence Garcia Joins The Vascular Care Group, Newton-Wellesley

Retrieved on: 
Tuesday, September 20, 2022
Health, Practice Management, Other Health, Managed Care, General Health, Cardiology, Definitive, MPH, Degenerative disease, Faculty, Time, American College, Master of Science, Tufts University School of Medicine, Beth Israel Deaconess Medical Center, Society, Health, Boston (magazine), Coronary artery disease, Medicare Physician Group Practice (PGP) Demonstration, Patient, Clinical trial, Physician, MBA, SCAI, University of Iowa Hospitals and Clinics, Moyamoya disease, Associate, Diagnosis, Board, FAHA, Harvard Medical School, Research, Vascular disease, American College of Cardiology, Interventional cardiology, Hospital, American Heart Association, Multimedia, FACC, University, RPVI, ST, FACS, Dentistry, Pharmaceutical industry, Medicine, Medical imaging, Cardiology, MD, Parkland Memorial Hospital, Medicine

The Vascular Care Group, a state-of-the art practice committed to the prevention, diagnosis and treatment of vascular disease, is pleased to announce that Dr. Lawrence Garcia has joined the Wellesley center.

Key Points: 
  • The Vascular Care Group, a state-of-the art practice committed to the prevention, diagnosis and treatment of vascular disease, is pleased to announce that Dr. Lawrence Garcia has joined the Wellesley center.
  • Lawrence A. Garcia, MD, FACC, FAHA, FSCAI, is a Board-certified interventional cardiologist with a focus on peripheral vascular disease.
  • Prior to joining The Vascular Care Group, Dr. Garcia received his undergraduate and doctoral degrees from the University of Arizona.
  • The Vascular Care Group (TVCG) is a growing group practice committed to the prevention, diagnosis and treatment of vascular disease.

Inari Medical Announces Results from the Fully Enrolled 800-patient US Cohort of the FlowTriever FLASH Registry

Retrieved on: 
Monday, September 19, 2022
RCT, Columbia University College of Dental Medicine, UPMC, Bleeding, Columbia University, MD, FDA, Principal, PERT, Interventional cardiology, Thrombosis, Pulmonary embolism, VTE, Patient, University of Pittsburgh Medical Center, Deep vein thrombosis, CE, Columbia University Irving Medical Center, Physician, Surgeon, ICU, European Association for the Study of the Liver, TCT, NASDAQ, Associate, PE, Association, GLOBE, FLASH, Mortality, University, FLAME, Disease, Maes, Pharmaceutical industry, EuroIntervention, Medicine

The data was also simultaneously published in EuroIntervention, the official journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

Key Points: 
  • The data was also simultaneously published in EuroIntervention, the official journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
  • FLASH is a prospective, multicenter, single-arm registry evaluating real-world patient outcomes after treatment of PE with FlowTriever.
  • We believe these results, in addition to the more than 35,000 patients treated commercially, reinforce FlowTriever as a front-line therapy for PE, said Thomas Tu, MD, Chief Medical Officer of Inari Medical.
  • Inari Medical, Inc. is a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases.

SUPIRA MEDICAL ANNOUNCES SUCCESSFUL FIRST-IN-HUMAN USE OF ITS NEXT GENERATION PERCUTANEOUS VENTRICULAR ASSIST DEVICE

Retrieved on: 
Friday, September 16, 2022
Safety, Trial of the century, LOS, Risk, Angioplasty, Percutaneous, Coronary artery disease, DRS, Patient, University of California, Davis, Physician, University Medical Center, Disease, CEO, Solution, CS, Cardiogenic shock, Hemodynamics, Heart, Interventional cardiology, University, Structural heart disease, Medical device, Medicine

LOS GATOS, Calif., Sept. 16, 2022 /PRNewswire/ -- Supira Medical, Inc., a Shifamed portfolio company focused on developing the next-generation solution for mechanical circulatory support, announced today it has initiated its first-in-human clinical study performed by principal investigator, Adrian Ebner, M.D., Head of the Cardiovascular Department at the Italian Hospital Asuncion Paraguay. The prospective, single-arm, single-center study will evaluate the safety and performance of Supira's low-profile, high-flow percutaneous ventricular assist device (pVAD) to support cardiovascular hemodynamics in patients undergoing high-risk percutaneous coronary interventions (HRPCI).

Key Points: 
  • The prospective, single-arm, single-center study will evaluate the safety and performance of Supira's low-profile, high-flow percutaneous ventricular assist device (pVAD) to support cardiovascular hemodynamics in patients undergoing high-risk percutaneous coronary interventions (HRPCI).
  • "Today marks an important milestone as Supira transitions to a clinical-stage company," commented Dr. Nitin Salunke, President and CEO of Supira Medical.
  • Percutaneous ventricular assist devices are used during stent placement or angioplasty to provide mechanical support for high-risk patients with severe coronary artery disease or comorbidities.
  • Supira Medical, a privately held portfolio company of Shifamed, is focused on development of a next generation percutaneous ventricular assist device for use in high-risk patients undergoing interventional procedures.

Philips showcases clinical data and solutions designed to deliver better cardiac care with greater efficiency at TCT 2022

Retrieved on: 
Friday, September 16, 2022
PVD, Safety, Journal, Efficiency, Beth Israel Deaconess Medical Center, Research, PHG, Patient, Physician, Technology, Cardiology, Control, Philips, Aortic valve, Electrophysiology, 2D, Revascularization, Instant, Pilot in command, American College, 3D, Assistant, Sale, Journal of Comparative Effectiveness Research, List of Dove Medical Press academic journals, Interventional cardiology, Treatment, PCI, Decision-making, Guideline, NYSE, MD, Association, EPIQ, Length of stay, Physiology, AEX, SAS, ISR, Moyamoya disease, ESC, Appropriate use criteria, Veni, vidi, vici, Workflow, Health, TAVR, Calendar, Journal of the American College of Cardiology, Solution, General manager, Telemetry, Harvard Medical School, JACC, MCOT, IVUS, TCT, Medical imaging, Medicine, Medical device, Silviculture, Medicine

In addition, the company will present key clinical data, including global consensus data which highlights the importance of IVUS for both arterial and venous procedures.

Key Points: 
  • In addition, the company will present key clinical data, including global consensus data which highlights the importance of IVUS for both arterial and venous procedures.
  • At Philips, we are fully focused on supporting physicians to improve the health and well-being of the patients they serve.
  • Visitors to TCT 2022 will have access to Philips latest solutions, plus opportunities to engage with clinical experts and experience innovative cardiac solutions.
  • Visit the Philips Engagement Hub to experience innovative cardiac solutions and follow the #TCT2022 conversation on @PhilipsLiveFrom throughout the event.

AVS Announces Multi-Site Enrollment of First Patients in POWER PAD I Clinical Trial and Appointment of William H. Kucheman to Board of Directors

Retrieved on: 
Thursday, September 15, 2022
Medical Devices, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Cardiology, FDA, Artery, Hank, University of Michigan, Population, POWER, Lithotripsy, Interventional cardiology, Industry, Generalized arterial calcification of infancy, Patient, CEO, State university system, BS, MBA, Technology, IVL, Royal Perth Hospital, AVS, Pennsylvania Hospital, Board of directors, Hillrom, PULSE, Dominican Republic, Pulse, Calcium, Board, Moyamoya disease, Elective surgery, Boston Scientific, Virginia Tech, Leg, University, Pharmaceutical industry, Medical imaging

AVS is only the second company to conduct a first-in-human study in the rapidly growing intravascular lithotripsy space.

Key Points: 
  • AVS is only the second company to conduct a first-in-human study in the rapidly growing intravascular lithotripsy space.
  • AVS is the first company to develop pulsatile intravascular lithotripsy, a therapy that is delivered through a balloon-based platform called PULSE.
  • We are excited by this first-in-human trial milestone we have achieved, added Mark Toland, President and Chief Executive Officer of AVS.
  • Kucheman added, I am delighted to join the AVS board and look forward to helping patients with limited treatment options.

Co-Author of the Karolinska 1000 Consecutive MANTA® Vascular Closure Device Study to Present Learnings at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Conference

Retrieved on: 
Thursday, September 15, 2022
Weck, Health, MANTA, Karolinska Institute, NYSE, Canadian International Council, SAFE, Anesthesia, VCDS, CRF, Percutaneous, Device, LMA, Interventional cardiology, TAVI, U.S. Securities and Exchange Commission, Patient, Emergency medicine, Karolinska University Hospital, Solution, Annual report, Clinical trial, Teleflex, VCD, International Journal of Cardiology, Security (finance), 1048, Observational study, GLOBE, Prostatic urethral lift, Urology, Catheter, Veni, vidi, vici, TFX, TCT, Radiology, MARVEL, Medical device, Medical imaging, Cardiology, Pilling, QuikClot

TCT is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the world's foremost educational forum specializing in interventional cardiovascular medicine.

Key Points: 
  • TCT is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the world's foremost educational forum specializing in interventional cardiovascular medicine.
  • The findings of our study indicate that the MANTA Device is easy to learn and has a short learning curve, which is in line with our user experience.
  • The MANTA Device is the first commercially available biomechanical vascular closure device designed specifically for large bore femoral arterial access site closure.
  • Percutaneous plug-based vascular closure device in 1000 consecutive transfemoral transcatheter aortic valve implantations.